JP2012533299A5 - - Google Patents

Download PDF

Info

Publication number
JP2012533299A5
JP2012533299A5 JP2012520638A JP2012520638A JP2012533299A5 JP 2012533299 A5 JP2012533299 A5 JP 2012533299A5 JP 2012520638 A JP2012520638 A JP 2012520638A JP 2012520638 A JP2012520638 A JP 2012520638A JP 2012533299 A5 JP2012533299 A5 JP 2012533299A5
Authority
JP
Japan
Prior art keywords
expression vector
promoter
nucleic acid
acid sequence
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012520638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012533299A (ja
JP5828838B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/036247 external-priority patent/WO2011008348A2/en
Publication of JP2012533299A publication Critical patent/JP2012533299A/ja
Publication of JP2012533299A5 publication Critical patent/JP2012533299A5/ja
Application granted granted Critical
Publication of JP5828838B2 publication Critical patent/JP5828838B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012520638A 2009-07-15 2010-05-26 ヒト免疫不全ウイルス阻害のための二重ベクター Expired - Fee Related JP5828838B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22568709P 2009-07-15 2009-07-15
US61/225,687 2009-07-15
US28759909P 2009-12-17 2009-12-17
US61/287,599 2009-12-17
PCT/US2010/036247 WO2011008348A2 (en) 2009-07-15 2010-05-26 Dual vector for inhibition of human immunodeficiency virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015163281A Division JP6247259B2 (ja) 2009-07-15 2015-08-21 ヒト免疫不全ウイルス阻害のための二重ベクター

Publications (3)

Publication Number Publication Date
JP2012533299A JP2012533299A (ja) 2012-12-27
JP2012533299A5 true JP2012533299A5 (enExample) 2013-07-11
JP5828838B2 JP5828838B2 (ja) 2015-12-09

Family

ID=42797105

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012520638A Expired - Fee Related JP5828838B2 (ja) 2009-07-15 2010-05-26 ヒト免疫不全ウイルス阻害のための二重ベクター
JP2015163281A Expired - Fee Related JP6247259B2 (ja) 2009-07-15 2015-08-21 ヒト免疫不全ウイルス阻害のための二重ベクター
JP2017220978A Expired - Fee Related JP6529141B2 (ja) 2009-07-15 2017-11-16 ヒト免疫不全ウイルス阻害のための二重ベクター
JP2019089588A Expired - Fee Related JP6840189B2 (ja) 2009-07-15 2019-05-10 ヒト免疫不全ウイルス阻害のための二重ベクター

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015163281A Expired - Fee Related JP6247259B2 (ja) 2009-07-15 2015-08-21 ヒト免疫不全ウイルス阻害のための二重ベクター
JP2017220978A Expired - Fee Related JP6529141B2 (ja) 2009-07-15 2017-11-16 ヒト免疫不全ウイルス阻害のための二重ベクター
JP2019089588A Expired - Fee Related JP6840189B2 (ja) 2009-07-15 2019-05-10 ヒト免疫不全ウイルス阻害のための二重ベクター

Country Status (9)

Country Link
US (3) US20120201794A1 (enExample)
EP (4) EP2949208B1 (enExample)
JP (4) JP5828838B2 (enExample)
AU (1) AU2010274031B2 (enExample)
CA (1) CA2767972A1 (enExample)
DK (2) DK3329772T3 (enExample)
ES (3) ES2657737T3 (enExample)
RU (2) RU2015133046A (enExample)
WO (1) WO2011008348A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12709753B2 (en) 2018-01-09 2026-08-18 American Gene Technologies International Inc. HIV immunotherapy with no pre-immunization step

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8909195D0 (en) 1989-04-22 1989-09-13 Cambridge Consultants Scoring system
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
GB201012410D0 (en) * 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
AP2014007348A0 (en) * 2011-06-29 2014-01-31 Ronilu Dev Corp Prevention and treatment of HIV infection
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
EP3027755B1 (en) * 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
WO2016014837A1 (en) * 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
DK3294893T5 (da) 2015-05-13 2024-10-07 Csl Behring Gene Therapy Inc Bioproduktion af lentivirale vektorer
CN108026593A (zh) * 2015-05-18 2018-05-11 卡琳缪恩股份有限公司 区分hiv-1与慢病毒载体的方法
CA2986469A1 (en) * 2015-05-18 2016-11-24 Calimmune, Inc. Gene therapeutic for the treatment of hiv and uses thereof
US11980663B2 (en) 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
IL297238B2 (en) 2016-01-15 2024-08-01 American Gene Tech Int Inc Methods and preparations for gamma-delta T-cell activation
JP7153332B2 (ja) * 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hivワクチン接種および免疫療法
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
CN105861559B (zh) * 2016-04-11 2018-05-01 苏州奥特铭医药科技有限公司 一种能直接反应i型干扰素应答的慢病毒载体及其制备方法与应用
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
CN106086075B (zh) * 2016-06-23 2019-08-06 福建医科大学 CXCR4RNAi慢病毒载体的构建方法
CA3028982A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
WO2018017882A1 (en) 2016-07-21 2018-01-25 American Gene Technologies International Inc. Viral vectors for treating parkinson's disease
KR20230093381A (ko) * 2017-01-09 2023-06-27 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 예비-면역화 단계가 없는 hiv 면역요법
CA3049980A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
CA3059348A1 (en) 2017-04-11 2018-10-18 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
US12559769B2 (en) 2017-06-16 2026-02-24 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
CA3070242A1 (en) 2017-07-18 2019-01-24 Calimmune, Inc. Compositions and methods for treating beta-hemoglobinopathies
AU2018348195B2 (en) 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JP7568507B2 (ja) * 2017-11-15 2024-10-16 ウィヤード・サイエンス・エルエルシー 非骨髄破壊的な骨髄再構成のための方法および組成物
MY207352A (en) 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
CA3106403A1 (en) 2018-07-15 2020-01-23 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy
EP3876952A4 (en) 2018-11-05 2022-08-24 American Gene Technologies International Inc. VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA
US12365873B2 (en) * 2021-01-28 2025-07-22 Allogene Therapeutics, Inc. Methods for transducing immune cells
RU2768032C1 (ru) * 2021-09-02 2022-03-23 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Генетическая конструкция для экспрессии генов mNG_CD4-CXCR4, рекомбинантная плазмида rVSV_mNG_CD4-CXCR4 и рекомбинантный штамм вируса везикулярного стоматита rVSV_mNG_CD4-CXCR4, обеспечивающий таргетный виролизис клеток, экспонирующих на своей поверхности белки gp120/gp 41 ВИЧ-1 тропности X4
RU2769125C1 (ru) * 2021-09-02 2022-03-28 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Генетическая конструкция для экспрессии генов mNG_CD4-CCR5, рекомбинантная плазмида rVSV_mNG_CD4-CCR5 и рекомбинантный штамм вируса везикулярного стоматита rVSV_mNG_CD4-CCR5, обеспечивающий таргетный виролизис клеток, экспонирующих на своей поверхности белки gp120/gp41 ВИЧ-1 тропности R5
AU2023292959A1 (en) * 2022-06-15 2024-12-19 Cedars-Sinai Medical Center Noncoding rna agents (bcyrn1 and derivatives thereof) to treat diseases of immunity
WO2026039311A1 (en) * 2024-08-10 2026-02-19 Vectorgen Lentiviral vector for treating human immunodeficiency virus infection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US7737124B2 (en) * 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
RU2324738C2 (ru) * 2006-06-16 2008-05-20 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) ГЕНЕТИЧЕСКАЯ КОНСТРУКЦИЯ НА ОСНОВЕ ВЕКТОРНОЙ ПЛАЗМИДЫ pEGFP-N1, ПРОДУЦИРУЮЩАЯ siPHK-ИНГИБИТОРЫ РЕПРОДУКЦИИ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА 1 ТИПА (ЕЕ ВАРИАНТЫ)
CN101841399B (zh) * 2009-03-16 2013-08-07 上海贝尔股份有限公司 多基站协作接收网络中实现同步上行harq进程的方法和装置
EP2456786B2 (en) * 2009-07-24 2017-04-19 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12709753B2 (en) 2018-01-09 2026-08-18 American Gene Technologies International Inc. HIV immunotherapy with no pre-immunization step

Similar Documents

Publication Publication Date Title
RU2012105281A (ru) Двойной вектор для подавления вируса иммунодефицита человека
AU2014296059B2 (en) Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors
JP2023071897A (ja) Hiv感染のrnaガイド処置のための方法および組成物
Bobbin et al. RNA interference approaches for treatment of HIV-1 infection
WO2017132112A1 (en) Methods and compositions for rna-guided treatment of hiv infection
US20210032627A1 (en) Gene therapeutic for the treatment of hiv and uses thereof
TW201602349A (zh) 抗hiv幹細胞及其用途
JP2018518196A5 (enExample)
Riley et al. Cell-mediated immunity to target the persistent human immunodeficiency virus reservoir
CN115720520A (zh) 用于预防和/或治疗哺乳动物疾病的组合物和方法
Khalid et al. Stem cell therapy and its significance in HIV infection
US20200061117A1 (en) Protective Chimeric Antigen Receptor Stem Cell Gene Therapy for Viral Infection
Lori et al. Gene therapy approaches to HIV infection
AU2017254831B2 (en) Dual vector for inhibition of human immunodeficiency virus
Re et al. Chimeric Antigen Receptor-Modified Immune Cells for Eradication of HIV Reservoirs
Sasson et al. Site‐specific host gene modification by zinc finger nucleases: pointing the way to drug free control of HIV‐1?
CN118103076A (zh) 可用于疾病治疗的慢病毒载体
Matamoros Inhibition of CCR5 and CXCR4 prevents HIV infection
Ledger et al. Cell-Delivered Gene Therapy for HIV
JPH1118779A (ja) 新規核酸及びそのエイズ発症抑制剤としての用途
HK1221488B (en) Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
TW200838873A (en) Inhibition of HIV replication and expression of p24 with eIF-5A